Does the media refer more to ANAB or RCKT?

In the previous week, AnaptysBio had 3 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 4 mentions for AnaptysBio and 1 mentions for Rocket Pharmaceuticals. AnaptysBio's average media sentiment score of 1.15 beat Rocket Pharmaceuticals' score of 0.82 indicating that AnaptysBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rocket Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, FBRX or RCKT?

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forte Biosciences N/A N/A -$69.38M -$4.65 N/A Rocket Pharmaceuticals N/A N/A -$223.12M -$0.17 N/A

Is FBRX or RCKT more profitable?

Rocket Pharmaceuticals' return on equity of -52.77% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Forte Biosciences N/A -94.82% -77.68% Rocket Pharmaceuticals N/A -52.77% -44.92%

Does the media refer more to FBRX or RCKT?

In the previous week, Forte Biosciences and Forte Biosciences both had 1 articles in the media. Rocket Pharmaceuticals' average media sentiment score of 0.82 beat Forte Biosciences' score of 0.00 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forte Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rocket Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, RCKT or BCAX?

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rocket Pharmaceuticals N/A N/A -$223.12M -$0.17 N/A Bicara Therapeutics N/A N/A -$137.95M -$3.10 N/A

Is RCKT or BCAX more profitable?

Bicara Therapeutics' return on equity of -41.49% beat Rocket Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Rocket Pharmaceuticals N/A -52.77% -44.92% Bicara Therapeutics N/A -41.49% -38.59%

Does the media favor RCKT or BCAX?

In the previous week, Bicara Therapeutics had 2 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 3 mentions for Bicara Therapeutics and 1 mentions for Rocket Pharmaceuticals. Bicara Therapeutics' average media sentiment score of 1.11 beat Rocket Pharmaceuticals' score of 0.82 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicara Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RCKT or NVAX?

In the previous week, Novavax had 4 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 5 mentions for Novavax and 1 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.82 beat Novavax's score of 0.61 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novavax 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MAZE or RCKT more profitable?

Maze Therapeutics' return on equity of -34.94% beat Rocket Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Maze Therapeutics N/A -34.94% -30.18% Rocket Pharmaceuticals N/A -52.77% -44.92%

Does the media favor MAZE or RCKT?

In the previous week, Maze Therapeutics had 29 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 30 mentions for Maze Therapeutics and 1 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.82 beat Maze Therapeutics' score of 0.34 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 18 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rocket Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rocket Pharmaceuticals (RCKT) Competitors

$3.71 -0.15 (-3.89%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$3.79 +0.08 (+2.16%)

As of 05:55 AM Eastern

Compare

RCKT vs. ANAB, FBRX, BCAX, NVAX, and MAZE

Should you buy Rocket Pharmaceuticals stock or one of its competitors? Rocket Pharmaceuticals's main competitors and comparable companies include AnaptysBio (ANAB), Forte Biosciences (FBRX), Bicara Therapeutics (BCAX), Novavax (NVAX), and Maze Therapeutics (MAZE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rocket Pharmaceuticals compare to AnaptysBio?

AnaptysBio (NASDAQ:ANAB) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

AnaptysBio has higher revenue and earnings than Rocket Pharmaceuticals. AnaptysBio is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	7.14	-$13.23M	-$1.08	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A

AnaptysBio currently has a consensus target price of $79.85, suggesting a potential upside of 41.07%. Rocket Pharmaceuticals has a consensus target price of $8.57, suggesting a potential upside of 131.04%. Given Rocket Pharmaceuticals' higher possible upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30

In the previous week, AnaptysBio had 3 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 4 mentions for AnaptysBio and 1 mentions for Rocket Pharmaceuticals. AnaptysBio's average media sentiment score of 1.15 beat Rocket Pharmaceuticals' score of 0.82 indicating that AnaptysBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rocket Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rocket Pharmaceuticals has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	N/A	-7.75%
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%

98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 31.5% of AnaptysBio shares are owned by company insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

AnaptysBio has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

Summary

AnaptysBio beats Rocket Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Forte Biosciences?

Forte Biosciences (NASDAQ:FBRX) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

In the previous week, Forte Biosciences and Forte Biosciences both had 1 articles in the media. Rocket Pharmaceuticals' average media sentiment score of 0.82 beat Forte Biosciences' score of 0.00 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forte Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rocket Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rocket Pharmaceuticals' return on equity of -52.77% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-94.82%	-77.68%
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%

Forte Biosciences presently has a consensus price target of $71.67, indicating a potential downside of 6.91%. Rocket Pharmaceuticals has a consensus price target of $8.57, indicating a potential upside of 131.04%. Given Rocket Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A

Forte Biosciences has a beta of 2.62, indicating that its share price is 162% more volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 4.4% of Forte Biosciences shares are held by company insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Rocket Pharmaceuticals beats Forte Biosciences on 10 of the 13 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Bicara Therapeutics?

Rocket Pharmaceuticals (NASDAQ:RCKT) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 21.3% of Rocket Pharmaceuticals shares are held by insiders. Comparatively, 13.8% of Bicara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Bicara Therapeutics had 2 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 3 mentions for Bicara Therapeutics and 1 mentions for Rocket Pharmaceuticals. Bicara Therapeutics' average media sentiment score of 1.11 beat Rocket Pharmaceuticals' score of 0.82 indicating that Bicara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bicara Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rocket Pharmaceuticals has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.82, meaning that its stock price is 182% less volatile than the broader market.

Rocket Pharmaceuticals presently has a consensus target price of $8.57, suggesting a potential upside of 131.04%. Bicara Therapeutics has a consensus target price of $32.64, suggesting a potential upside of 37.65%. Given Rocket Pharmaceuticals' higher possible upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80

Bicara Therapeutics' return on equity of -41.49% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%
Bicara Therapeutics	N/A	-41.49%	-38.59%

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A

Summary

Bicara Therapeutics beats Rocket Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Novavax?

Rocket Pharmaceuticals (NASDAQ:RCKT) and Novavax (NASDAQ:NVAX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

Novavax has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A
Novavax	$413.80M	4.06	$440.30M	-$1.52	N/A

In the previous week, Novavax had 4 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 5 mentions for Novavax and 1 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.82 beat Novavax's score of 0.61 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rocket Pharmaceuticals presently has a consensus price target of $8.57, suggesting a potential upside of 131.04%. Novavax has a consensus price target of $14.00, suggesting a potential upside of 37.39%. Given Rocket Pharmaceuticals' higher possible upside, research analysts plainly believe Rocket Pharmaceuticals is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Rocket Pharmaceuticals has a net margin of 0.00% compared to Novavax's net margin of -59.87%. Novavax's return on equity of -14.82% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%
Novavax	-59.87%	-14.82%	-13.35%

Rocket Pharmaceuticals has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, Novavax has a beta of 2.45, meaning that its share price is 145% more volatile than the broader market.

98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 21.3% of Rocket Pharmaceuticals shares are owned by insiders. Comparatively, 1.6% of Novavax shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Novavax beats Rocket Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Maze Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Maze Therapeutics has a beta of 2.17, indicating that its stock price is 117% more volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

Maze Therapeutics presently has a consensus target price of $66.00, indicating a potential upside of 150.28%. Rocket Pharmaceuticals has a consensus target price of $8.57, indicating a potential upside of 131.04%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Maze Therapeutics is more favorable than Rocket Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.08
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30

Maze Therapeutics has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$20M	73.24	-$131.12M	-$2.52	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A

In the previous week, Maze Therapeutics had 29 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 30 mentions for Maze Therapeutics and 1 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.82 beat Maze Therapeutics' score of 0.34 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	18 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rocket Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maze Therapeutics' return on equity of -34.94% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-34.94%	-30.18%
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%

98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 5.3% of Maze Therapeutics shares are owned by company insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Maze Therapeutics beats Rocket Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Get Rocket Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RCKT vs. The Competition

Export

Metric	Rocket Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$423.73M	$4.01B	$7.38B	$12.89B
Dividend Yield	N/A	3.60%	2.54%	9.14%
P/E Ratio	-21.82	12.50	270.75	25.39
Price / Sales	N/A	1,491.38	660.64	98.81
Price / Cash	N/A	108.60	77.07	52.39
Price / Book	1.45	15.97	10.88	6.40
Net Income	-$223.12M	-$22.81M	$3.48B	$358.18M
7 Day Performance	-3.89%	-0.88%	-0.98%	0.04%
1 Month Performance	2.77%	4.81%	2.90%	-0.80%
1 Year Performance	15.58%	47.25%	22.18%	12.47%

Rocket Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RCKT Rocket Pharmaceuticals	2.8997 of 5 stars	$3.71 -3.9%	$8.57 +131.0%	+13.8%	$423.73M	N/A	N/A	240	Gap Down
ANAB AnaptysBio	3.0065 of 5 stars	$57.03 +1.3%	$79.85 +40.0%	+155.1%	$1.67B	$234.60M	N/A	100	Positive News Gap Down
FBRX Forte Biosciences	0.9931 of 5 stars	$76.99 flat	$71.67 -6.9%	N/A	$1.63B	N/A	N/A	5
BCAX Bicara Therapeutics	2.1806 of 5 stars	$23.12 -1.3%	$32.64 +41.2%	+92.9%	$1.55B	N/A	N/A	32	Positive News Gap Down
NVAX Novavax	1.8172 of 5 stars	$9.37 +1.2%	$14.00 +49.4%	+31.8%	$1.53B	$1.12B	N/A	1,990

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RCKT) was last updated on 9/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rocket Pharmaceuticals (RCKT) Competitors

RCKT vs. ANAB, FBRX, BCAX, NVAX, and MAZE

How does Rocket Pharmaceuticals compare to AnaptysBio?

Summary

How does Rocket Pharmaceuticals compare to Forte Biosciences?

Summary

How does Rocket Pharmaceuticals compare to Bicara Therapeutics?

Summary

How does Rocket Pharmaceuticals compare to Novavax?

Summary

How does Rocket Pharmaceuticals compare to Maze Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT vs. The Competition

Rocket Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rocket Pharmaceuticals (RCKT) Competitors

RCKT vs. ANAB, FBRX, BCAX, NVAX, and MAZE

How does Rocket Pharmaceuticals compare to AnaptysBio?

Which has preferable valuation and earnings, ANAB or RCKT?

Do analysts prefer ANAB or RCKT?

Does the media refer more to ANAB or RCKT?

Is ANAB or RCKT more profitable?

Do institutionals & insiders hold more shares of ANAB or RCKT?

Which has more risk & volatility, ANAB or RCKT?

Summary

How does Rocket Pharmaceuticals compare to Forte Biosciences?

Does the media refer more to FBRX or RCKT?

Is FBRX or RCKT more profitable?

Do analysts rate FBRX or RCKT?

Which has better valuation and earnings, FBRX or RCKT?

Which has more risk and volatility, FBRX or RCKT?

Do institutionals and insiders have more ownership in FBRX or RCKT?

Summary

How does Rocket Pharmaceuticals compare to Bicara Therapeutics?

Do insiders and institutionals have more ownership in RCKT or BCAX?

Does the media favor RCKT or BCAX?

Which has more risk and volatility, RCKT or BCAX?

Do analysts rate RCKT or BCAX?

Is RCKT or BCAX more profitable?

Which has higher valuation and earnings, RCKT or BCAX?

Summary

How does Rocket Pharmaceuticals compare to Novavax?

Which has higher earnings & valuation, RCKT or NVAX?

Does the media refer more to RCKT or NVAX?

Do analysts prefer RCKT or NVAX?

Is RCKT or NVAX more profitable?

Which has more risk & volatility, RCKT or NVAX?

Do insiders and institutionals hold more shares of RCKT or NVAX?

Summary

How does Rocket Pharmaceuticals compare to Maze Therapeutics?

Which has more volatility & risk, MAZE or RCKT?

Do analysts rate MAZE or RCKT?

Which has higher earnings and valuation, MAZE or RCKT?

Does the media favor MAZE or RCKT?

Is MAZE or RCKT more profitable?

Do insiders & institutionals have more ownership in MAZE or RCKT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT vs. The Competition

Rocket Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools